22:01 , Jun 10, 2019 |  BC Extra  |  Company News

Tilos takeout sees Merck tapping TGFβ to solve checkpoint resistance

In its ongoing quest to find combinations for Keytruda pembrolizumab, Merck is acquiring two-year-old Tilos for its ability to modulate TGFβ, a target that’s been gaining interest on the back of clinical data in immuno-oncology,...
23:46 , Jun 4, 2019 |  BC Extra  |  Company News

June 4 Company Quick Takes: Lilly's Emgality gets expanded indication; plus Vimizim, Zerbaxa and more

Emgality gets U.S. approval for episodic cluster headaches  FDA approved Emgality galcanezumab-gnlm from Eli Lilly and Co. (NYSE:LLY) to treat episodic cluster headache in adults. The anti-CGRP mAb is already approved as a prophylaxis for...
22:44 , Apr 25, 2019 |  BC Extra  |  Clinical News

Gilead looks towards NASH combo data after selonsertib fails in second Phase III

Gilead's selonsertib has failed in another Phase III NASH trial, this time missing the primary endpoint in patients with a less severe stage of fibrosis. The company will focus on its combination strategy to treat...
12:21 , Apr 16, 2019 |  BC Extra  |  Company News

With insitro deal, Gilead turns to machine learning to unlock new NASH targets

Not yet content with the trio of clinical programs in its pipeline, Gilead has struck its third NASH deal this year, this time banking on machine learning company insitro to develop disease models and discover...
02:22 , Apr 5, 2019 |  BC Innovations  |  Tools & Techniques

Second shot for shRNA

Having long been demoted to tool compound status, shRNA is gaining renewed attention as a therapeutic modality by offering a simpler path to creating next-generation cell therapies than gene editing. Celyad has jumped in, using...
22:34 , Apr 4, 2019 |  BC Extra  |  Clinical News

Kolon TissueGene tumbles on mislabeling revelation for cell therapy Invossa

Kolon TissueGene suspended enrollment in a U.S. Phase III trial of Invossa after finding that the osteoarthritis therapy's TGFB1-expressing component is derived from kidney cells rather than cartilage cells as it previously thought. Kolon TissueGene...
21:57 , Feb 14, 2019 |  BC Innovations  |  Emerging Company Profile

Indalo: Integral to fibrosis

Indalo Therapeutics Inc. is targeting the root causes in fibrosis by antagonizing multiple integrins simultaneously to disrupt disease-associated processes, not just those driven by a single integrin or TGFβ signaling. Indalo President and CEO Robert...
00:14 , Feb 9, 2019 |  BioCentury  |  Product Development

Merck KGaA's large-scale partnering

Merck KGaA's deal with GlaxoSmithKline plc to develop cancer therapy M7824 enables Merck to pursue a more ambitious development plan than it could have done by going it alone, and provides a template for how...
17:54 , Jan 11, 2019 |  BC Week In Review  |  Company News

Gilead gets rights to NASH candidates from Yuhan

Continuing to grow its fibrosis pipeline, Gilead Sciences Inc. (NASDAQ:GILD) licensed ex-Korean rights from Yuhan Corp. (KSE:000100) to develop small molecules against two undisclosed targets to treat advanced fibrosis due to non-alcoholic steatohepatitis. The deal...
22:56 , Jan 9, 2019 |  BC Extra  |  Company News

Elevian, AI company Insilico partner to find anti-aging candidates in GDF11 pathway

Elevian Inc. (Allston, Mass.) partnered with AI company Insilico Medicine Inc. (Baltimore, Md.) to use deep-learning technology to discover small molecules that target the GDF11 pathway to treat age-related diseases. Insilico will apply its generative...